In the first issue of Deep Dive for 2019, we look at disruptive technologies in pharma, how they're changing medicine, research and development, and healthcare, and how the
The FDA has approved Akebia Therapeutics’ vadadustat as a treatment for anaemia caused by chronic kidney disease (CKD) in dialysis patients, becoming the first rival to GS